Dendreon picks CMO PharmaCell to make Provenge in Europe

Dutch CMO PharmaCell has inked a deal with the struggling Dendreon ($DNDN) to manufacture its prostate cancer drug Provenge in Europe. The injection won European approval in September, and the agreement is part of a two-year relationship between the two companies. More